The name Magrolimab only listed one that had 440 patients in p1b/2, not sure if it is completely enrolled. I looked up the original name, Hu5F9-G4, and it has a couple completed phase 1 trials, the first lists 88 patients.

https://clinicaltrials.gov/ct2/results?cond=&...&dist=

For safety, I found this,
https://www.ncbi.nlm.nih.gov/pubmed/30811285
On the basis of tolerability and receptor occupancy studies that showed 100% CD47 saturation on RBCs, 1 mg/kg was selected as the priming dose. In subsequent groups, patients were treated with maintenance doses that ranged from 3 to 45 mg/kg, and most toxicities were mild to moderate. These included transient anemia (57% of patients), hemagglutination on peripheral blood smear (36%), fatigue (64%), headaches (50%), fever (45%), chills (45%), hyperbilirubinemia (34%), lymphopenia (34%), infusion-related reactions (34%), and arthralgias (18%).